Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...
Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...
Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.
Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...
As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...
In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus ...
Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.
A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...